(Q33614786)

English

Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, rad

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, rad (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

0 references

rheumatoid arthritis

0 references

1 reference

based on heuristic

inferred from title

Désirée van der Heijde

3

object named as

Désirée van der Heijde

0 references

author name string

Jun Hashimoto

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Patrick Garnero

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Nobuyuki Miyasaka

4

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Kazuhiko Yamamoto

5

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Shinichi Kawai

6

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Tsutomu Takeuchi

7

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Hideki Yoshikawa

8

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Norihiro Nishimoto

9

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

publication date

24 June 2010

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Modern Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

10-15

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3036807

21 June 2018

Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3036807

21 June 2018

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3036807

21 June 2018

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3036807

21 June 2018

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3036807

21 June 2018

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3036807

21 June 2018

Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

1 reference

https://api.crossref.org/works/10.3109%2FS10165-010-0325-3

21 January 2018

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial

1 reference

https://api.crossref.org/works/10.3109%2FS10165-010-0325-3

21 January 2018

A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3036807

30 October 2018

Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3036807

30 October 2018

Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers

1 reference

https://pubmed.ncbi.nlm.nih.gov/20574648

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

How to read radiographs according to the Sharp/van der Heijde method

1 reference

https://pubmed.ncbi.nlm.nih.gov/20574648

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20574648

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20574648

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

https://pubmed.ncbi.nlm.nih.gov/20574648

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3109/S10165-010-0325-3

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

release_vfoxry646zhkhetllsfm4xjrxm

1 reference

https://api.fatcat.wiki/v0/release/vfoxry646zhkhetllsfm4xjrxm

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33614786&oldid=1982220330"